Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature.
Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature.
复制标题
DOI：
10.1155/2016/2596423
复制
发表时间：
2016
影响因子：
0.9
通讯作者：
Brown A
中科院分区：
文献类型：
--
作者：
Delacruz W;Setlik R;Hassantoufighi A;Daya S;Cooper S;Selby D;Brown A
非霍奇金淋巴瘤（NHL）是一组异质性血液恶性肿瘤，通常对标准一线化学免疫治疗方案有反应。不幸的是，患有难治性NHL的患者面临不良预后，并且代表了对改进治疗的未满足的需求。我们介绍了2例对基于维布妥昔单抗（BV）的新型方案有应答的难治性CD 30 + NHL病例。第1例患者为伴有颅神经受累的IV期间变性大细胞淋巴瘤（ALCL），一线治疗环磷酰胺、多柔比星、长春新碱、依托泊苷和泼尼松（CHOEP）和二线环磷酰胺、长春新碱、多柔比星、地塞米松交替高剂量甲氨蝶呤（MTX）和阿糖胞苷失败（hyperCVAD）与鞘内-（IT-）MTX和IT-阿糖胞苷，但响应时BV取代长春新碱（hyperCBAD）。第2例患者是一例IV期弥漫性大B细胞淋巴瘤（DLBCL）伴软脑膜受累的男性，其疾病在一线利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松（R-CHOP）治疗期间进展，尽管接受了利妥昔单抗、地塞米松、阿糖胞苷和顺铂（R-DHAP）挽救治疗，但仍进展，其中在拓扑替康基础上加用BV导致显著缓解。本报告描述了第一次成功的挽救治疗高度侵袭性，双重难治性CD 30 + NHL使用两个未报告的BV为基础的化学免疫治疗方案。这两种方案似乎都有效，并且毒性可控。需要开展进一步的临床试验评估新型BV联合用药。
Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of hematologic malignancies which typically respond to standard first-line chemoimmunotherapy regimens. Unfortunately, patients with refractory NHL face a poor prognosis and represent an unmet need for improved therapeutics. We present two cases of refractory CD30+ NHL who responded to novel brentuximab vedotin- (BV-) based regimens. The first is a patient with stage IV anaplastic large cell lymphoma (ALCL) with cranial nerve involvement who failed front-line treatment with cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (CHOEP) and second line cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with high-dose methotrexate (MTX), and cytarabine (hyperCVAD) with intrathecal- (IT-) MTX and IT-cytarabine, but responded when BV was substituted for vincristine (hyperCBAD). The second patient was a man with stage IV diffuse large B-cell lymphoma (DLBCL) with leptomeningeal involvement whose disease progressed during first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and progressed despite salvage therapy with rituximab, dexamethasone, cytarabine, and cisplatin (R-DHAP) in whom addition of BV to topotecan resulted in a significant response. This report describes the first successful salvage treatments of highly aggressive, double refractory CD30+ NHL using two unreported BV-based chemoimmunotherapy regimens. Both regimens appear effective and have manageable toxicities. Further clinical trials assessing novel BV combinations are warranted.
登录
查看更多内容
影响因子：
51.1
作者：
Younes, Anas;Connors, Joseph M.;Ansell, Stephen M.
通讯作者：
Ansell, Stephen M.
影响因子：
37.3
作者：
Camicia R;Winkler HC;Hassa PO
通讯作者：
Hassa PO
影响因子：
45.3
作者：
Kim, Youn H.;Tavallaee, Mahkam;Horwitz, Steven M.
通讯作者：
Horwitz, Steven M.
影响因子：
28.5
作者：
Bartlett NL;Chen R;Fanale MA;Brice P;Gopal A;Smith SE;Advani R;Matous JV;Ramchandren R;Rosenblatt JD;Huebner D;Levine P;Grove L;Forero-Torres A
通讯作者：
Forero-Torres A
影响因子：
20.3
作者：
Jacobsen, Eric D.;Sharman, Jeff P.;Bartlett, Nancy L.
通讯作者：
Bartlett, Nancy L.